Bioresorbable Scaffolds versus Metallic Stents in Routine PCI.

PubWeight™: 5.42‹?› | Rank: Top 1%

🔗 View Article (PMID 28402237)

Published in N Engl J Med on March 29, 2017

Authors

Joanna J Wykrzykowska1, Robin P Kraak1, Sjoerd H Hofma1, Rene J van der Schaaf1, E Karin Arkenbout1, Alexander J IJsselmuiden1, Joëlle Elias1, Ivo M van Dongen1, Ruben Y G Tijssen1, Karel T Koch1, Jan Baan1, M Marije Vis1, Robbert J de Winter1, Jan J Piek1, Jan G P Tijssen1, Jose P S Henriques1, AIDA Investigators

Author Affiliations

1: From the AMC Heartcenter, Academic Medical Center-University of Amsterdam (J.J.W., R.P.K., J.E., I.M.D., R.Y.G.T., K.T.K., J.B., M.M.V., R.J.W., J.J.P., J.G.P.T., J.P.S.H.), and the Department of Cardiology, Onze Lieve Vrouwe Gasthuis (R.J.S.), Amsterdam, the Department of Cardiology, Medical Center Leeuwarden, Leeuwarden (S.H.H.), the Department of Cardiology, Tergooi Hospital, Blaricum (E.K.A.), and the Department of Cardiology, Albert Schweitzer Hospital, Dordrecht (A.J.IJ.) - all in the Netherlands.

Associated clinical trials:

Amsterdam Investigator-initiateD Absorb Strategy All-comers Trial (AIDA) | NCT01858077